Zoetis stock

Simple math: 15 (multiple) x $6.15 Earnings per Share = $ 92 per share "intrinsic value"

Mr. Market price $ 74  "margin of safety" 20%  

It seems that the stock is down, partly because the stock is down... 

Zoetis (ZTS) stock has experienced a significant downturn recently, primarily driven by a disappointing second-quarter 2026 earnings report and a sharp reduction in the company's full-year outlook.

Here is a breakdown of the key factors weighing on the stock:

• Slashed 2026 Guidance: While Zoetis beat its Q2 adjusted earnings per share (EPS) estimates, it missed revenue expectations and drastically cut its full-year 2026 guidance. The company lowered its expected EPS to $6.15–$6.25 (down from prior estimates) and reduced its revenue outlook, signaling negative organic operational growth.
  
  
• Softer Pet-Care Demand: CEO Kristin Peck highlighted a pressured U.S. companion-animal market. The company is seeing a decline in veterinary clinic visits and increased price sensitivity among pet owners, which has reduced demand across parts of its portfolio.
  
  
• Intensifying Competition: Zoetis is facing heavier competition, particularly in its highly profitable dermatology (Apoquel and Cytopoint) and parasiticide franchises. The entry of generic alternatives for some of its blockbuster drugs has further pressured sales in the companion-animal segment.
  
  
• Wave of Analyst Downgrades: The combination of weak guidance and market headwinds triggered a series of price-target reductions and downgrades from major financial institutions, including William Blair, JPMorgan, and UBS, which further accelerated the stock's slide.
  
  
• C-Suite Transition: Alongside the Q2 earnings, Zoetis announced a major leadership reshuffle, appointing Jay Saccaro as the new Executive Vice President, Chief Financial Officer, and Chief Operating Officer.   While meant to consolidate oversight, executive transitions can sometimes introduce short-term uncertainty for investors.
  
  

Although the company's livestock segment has shown strength, it has not been enough to offset the broader concerns surrounding its core companion-animal business.